Beaufort Securities reiterated Advanced Oncotherapy PLC (LON:AVO) to Speculative Buy in a report released today.
- Updated: October 2, 2016
Beaufort Securities has reiterated Advanced Oncotherapy PLC (LON:AVO) to Speculative Buy in a report released on 10/03/2016.
Yesterday Advanced Oncotherapy PLC (LON:AVO) traded 1.27% higher at 108.00GBX. The company’s 50-day moving average is 119.96GBX and its 200-day moving average is 147.34GBX. The last stock close price is down -25.77% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 6,669 shares of the stock were exchanged, down from an average trading volume of 71,242
See Chart Below
With a total market value of 0 GBX, Advanced Oncotherapy PLC has with a one year low of 98.00GBX and a one year high of 217.25GBX .
More About Advanced Oncotherapy PLC (LON:AVO)
Advanced Oncotherapy Plc is focused on providing radiotherapy systems for cancer treatment through the use of a proton therapy technology. The Company is engaged in development and then building of the Linac Image Guided Hadron Technology (LIGHT) proton beam cancer therapy device and management of healthcare related property. The Company's segments include Development of Proton Therapy-UK; Development of Proton Therapy-Switzerland; Development of Proton Therapy-USA, and Healthcare-related properties-UK. Its LIGHT system uses accelerators, which is a series of modular units. This feature offers hospitals and centers to customize treatment plans based on a range of energies. The Company's Research and development/ADAM S.A. (R&D/ADAM) facility is located on the campus of European Council for Nuclear Research (CERN), Geneva, Switzerland, and a manufacturing plant, clinical research and clinician training facility in Syracuse, the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.